---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-021306"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:43:46.364404+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Oncotelic completes merger transferring patent portfolio to Lunai for $20M Series B Preferred stock

## Summary
- Oncotelic contributed patent portfolio to Neurobridge Holdings, which merged into Lunai subsidiary; Oncotelic received 5 Series B shares (stated value $12.5M).
- Shares convertible at $1.50/common, but conversion requires stockholder approval; no conversion allowed before approval.
- Oncotelic retains perpetual, exclusive, royalty-free license to use the patents except for Biodefense and Alzheimer's fields.
- Oncotelic agreed to issue 10% of fully diluted shares to Autotelic upon uplisting in exchange for assets including peptide Y, PTH, insulin formulations.
- All transactions completed May 1, 2026; no cash exchanged.

## SEC filing metadata
- accession: 0001493152-26-021306
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 1.01, 2.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315226021306/0001493152-26-021306-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315226021306/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-021306
- JSON: https://secwatch.observer/filing/0001493152-26-021306.json
- Plain text: https://secwatch.observer/filing/0001493152-26-021306.txt

## Source-grounded claims
- claim_id: 5e3b8c0980decb4b3efa7206248d1532e5cc3d09
  claim: Oncotelic Therapeutics, Inc. completed an acquisition involving Lunai Bioworks, Inc. for aggregate stated value of $20,000,000 (closed 2026-05-01).
  evidence_excerpt: greement and Plan of Merger (the “Merger Agreement”) with Lunai Bioworks, Inc., a Delaware corporation (“Lunai”), Lunai Bioworks IP, Inc., a Delaware corporation and a wholly owned subsidiary of Lunai (“Merger Sub”), Neurobridge IP Holdings
  evidence_url: https://www.sec.gov/Archives/edgar/data/908259/000149315226021306/0001493152-26-021306-index.htm
- claim_id: 6b37d4b8c4e86c867ddcee4085e7fef3f518b0fa
  claim: Oncotelic Therapeutics, Inc. entered into Asset Transfer Agreement with Autotelic Inc. (effective 2026-04-30).
  evidence_excerpt: On April 30, 2026, the Company and Autotelic Inc. (“Autotelic”) entered into an asset transfer agreement (the “Asset Transfer Agreement”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/908259/000149315226021306/0001493152-26-021306-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.